Moreover, for irisin to be recognized as a significant biomarker in liver diseases, including NAFLD, there is a need for a greater number of clinical studies and the development of accurate and specific laboratory tests that would enable the diagnosis of liver diseases based on changes in irisin concentration. This evidence concerns the gene FNDC5 and metabolic dysfunction-associated steatotic liver disease.